{"id":"NCT02617589","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)","officialTitle":"A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-01","primaryCompletion":"2019-01-17","completion":"2022-03-04","firstPosted":"2015-12-01","resultsPosted":"2021-02-03","lastUpdate":"2023-03-28"},"enrollment":560,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Brain Cancer"],"interventions":[{"type":"DRUG","name":"Nivolumab","otherNames":[]},{"type":"DRUG","name":"Temozolomide","otherNames":[]},{"type":"RADIATION","name":"Radiotherapy","otherNames":[]}],"arms":[{"label":"Nivolumab + Radiotherapy Arm","type":"EXPERIMENTAL"},{"label":"Temozolomide + Radiotherapy Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"up to 3 years","effectByArm":[{"arm":"Nivolumab + Radiation Therapy","deltaMin":13.4,"sd":null},{"arm":"Temozolomide + Radiation Therapy","deltaMin":14.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0037"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":125,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Poland","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["35419607","32691060"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.BMSStudyConnect.com"]},"adverseEventsSummary":{"seriousAny":{"events":206,"n":278},"commonTop":["Fatigue","Headache","Nausea","Alopecia","Constipation"]}}